This brand name is authorized in Estonia, Ireland, Poland

Active ingredients

The drug ABECMA contains one active pharmaceutical ingredient (API):

1 Idecabtagene vicleucel

Idecabtagene vicleucel is a chimeric antigen receptor (CAR)-positive T cell therapy targeting B-cell maturation antigen (BCMA), which is expressed on the surface of normal and malignant plasma cells. The CAR construct includes an anti-BCMA scFv-targeting domain for antigen specificity, a transmembrane domain, a CD3-zeta T cell activation domain, and a 4-1BB costimulatory domain. Antigen-specific activation of idecabtagene vicleucel results in CAR-positive T cell proliferation, cytokine secretion and subsequent cytolytic killing of BCMA-expressing cells.

Read about Idecabtagene vicleucel

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
ABECMA Dispersion for infusion European Medicines Agency (EU) MPI, EU: SmPC

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1860140
Country: PL Rejestru Produktรณw Leczniczych Identifier(s): 100457776

ยฉ All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.